TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Neurotech International ( (AU:NTI) ).
Neurotech International has reported promising results from its pharmacokinetic study of NTI164, a CBDA-rich cannabinoid formulation, demonstrating its safety and efficacy for paediatric use. The study supports NTI164’s potential as a treatment for neurological disorders, with ongoing regulatory submissions in the US and Australia. Additionally, NTI164 has shown significant clinical improvements in Rett Syndrome, with results published in a scientific journal, highlighting its therapeutic potential and reinforcing its regulatory advancement prospects.
More about Neurotech International
Neurotech International Ltd is a clinical-stage biopharmaceutical company focused on developing treatments for paediatric neurological disorders. The company is advancing its proprietary cannabinoid formulation, NTI164, which targets conditions like autism spectrum disorder, Rett Syndrome, and PANDAS/PANS, with a focus on anti-inflammatory and neuroprotective properties.
Average Trading Volume: 592,901
Technical Sentiment Signal: Sell
Current Market Cap: A$23.09M
See more insights into NTI stock on TipRanks’ Stock Analysis page.